Clinical and Instrumental (Magnetic Resonance Imaging [MRI] and Multimodal Evoked Potentials) Follow-Up of Brain Lesions in Three Young Patients With Neurofibromatosis 1

Abstract

Diagnosis of neurofibromatosis 1 is based on clinical criteria. In a large number of children with neurofibromatosis 1, magnetic resonance imaging (MRI) reveals high-signal T₂-weighted intensities in different brain regions, defined as unidentified bright objects. These lesions are asymptomatic; most of them regress spontaneously with age, but the presence of contrast enhancement or mass effect in them usually strongly suggests an increased risk of proliferative changes. To date, few studies have focused on evoked potentials in patients with neurofibromatosis 1, and the reported abnormalities did not have significant clinical correlations. We describe the clinical and instrumental (MRI and evoked potentials) follow-up of three patients with neurofibromatosis 1. MRI and evoked potentials showed subclinical involvement of the central nervous system. Some MRI T₂-weighted hyperintensities showed enhancement and mass effect of uncertain significance. During follow-up, the MRI lesions spontaneously decreased in size or enhancement, allowing us to exclude the hypothesis of proliferative lesions; in the same way, some asymptomatic evoked potential abnormalities disappeared. These findings suggest that both MRI and evoked potentials could be useful in the detection and monitoring of cerebral complications of neurofibromatosis 1.

Get full access to this article

View all access options for this article.

References

Von Recklinghausen F: Uber die Multiplen Fibrome der Haut und Ihre Beziehungen zu Multiplen Neuromen, Berlin, August Hirschwald, 1882.

National Institutes of Health Consensus Development Conference: Neurofibromatosis conference statement. Arch Neurol 1988;45:575–578.

Friedman JM : Neurofibromatosis 1: Clinical manifestations and diagnostic criteria. J Child Neurol 2002;17:548–554.

Young H , Hyman S , North K : Neurofibromatosis 1: Clinical review and exceptions to the rules. J Child Neurol 2002;17:613–621.

Li Y , O'Connel P , Huntsman-Breidenbach HH , et al: Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics 1995;25:9–18.

Viskochil D : Genetic of neurofibromatosis 1 and NF1 gene. J Child Neurol 2002;17:562–570.

Bruce RK : Clinical features and pathobiology of neurofibromatosis 1. J Child Neurol 2002;17:573–577.

Listernick R , Charrow J , Greenwald MJ , Esterly NB : Optic gliomas in children with neurofibromatosis type 1. J Pediatr 1989;114:788–792.

Diebler C , Dulac O : Pediatric Neurology and Neuroradiology. Berlin: Springer-Verlag, 1987, 99–101.

10.

Aoki S , Barkovich AJ , Nishimura K , et al: Neurofibromatosis types 1 and 2: Cranial MR findings. Radiology 1989;172:527–534.

11.

Goldstein SM , Curless RG , Donovan Post MJ , Quencer RM : A new sign of neurofibromatosis on magnetic resonance imaging of children. Arch Neurol 1989;46:1222–1224.

12.

Perniola T, Margari L, Buttiglione M, et al: RMN e Potenziali Evocati Multimodali Nella Neurofibromatosi Tipo 1. Atti del XV Congresso Nazionale Della Società Italiana di Neuropsichiatria Infantile (S.I.N.P.I.) 1992;1:189–196.

13.

Braffman B , Naidich TP : Neurofibromatosis and tuberous sclerosis. Neuroimaging Clin North Am 1994;4:299–324.

14.

Griffiths PD , Blaser S , Mukonoweshuro W , et al: Neurofibromatosis bright objects in children wuth neurofibromatosis type 1: A proliferative potential? Pediatrics 1999;104(4):e49–e49.

15.

Bonawitz C , Castillo M , Chin CT , et al: Usefulness of contrast material in MR of patients with neurofibromatosis type 1. AJNR Am J Neuroradiol 1998;19:541–546.

16.

Ferner RE , Chaudhuri R , Bingham J , et al: MRI in neurofibromatosis 1. The nature and evolution of increased intensity T2 weighted lesions and their relationship to intellectual impairment. J Neurol Neurosurg Psychiatry 1993;56:492–495.

17.

North K , Hyman S , Barton B : Cognitive deficits in neurofibromatosis 1. J Child Neurol 2002;17:605–612.

18.

DeBella K , Szudek J , Fiedman JM : Use of the National Institutes of Health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 2000;105:608–614.

19.

Raininko R , Thelin L , Eeg-Olofsson O : Atypical focal non-neoplastic brain changes in neurofibromatosis type 1: Mass effect and contrast enhancement. Neuroradiology 2001;43:586–590.

20.

Jabbari B , Maitland CG , Morris LM , et al: The value of visual evoked potential as a screening test in neurofibromatosis. Arch Neurol 1985;42:1072–1074.

21.

Duffner PK , Cohen ME , Seidel FG , Shucard DW : The significance of MRI abnormalities in children with neurofibromatosis. Neurology 1989;39:373–378.

22.

Pensak ML , Keith RW , Dignan PS , et al: Neuroaudiologic abnormalities in patients with type 1 neurofibromatosis. Laryngoscope 1989;99:702–706.

23.

Loth D , Teyssou M , Avan P , et al: Comparative results of data of brain stem auditory evoked potentials and imaging during an evaluation of the course of Recklinghausen's neurofibromatosis. Ann Otolaryngol Chir Cervicofac 1989;113:239–244.

24.

Bravaccio F, Ammendola A, Cantore R, Ugolini G: Potenziali evocati cerebrali e neurofibromatosi tipo 1: Studio di 18 casi. Nuova Riv Neurol 1994;7:12–15.

25.

Pikus AT : Pediatric audiologic profile in type 1 and type 2 neurofibromatosis. Am Acad Audiol 1995;6:54–62.

26.

Iannaccone A , McCluney RA , Brewer VR , et al: Visual evoked potentials in children with neurofibromatosis type 1. Doc Ophthalmol 2002;105:63–81.

27.

Donchin E , Callaway E , Cooper R , et al: Publication criteria for studies of evoked potentials (EP) in man. Report of the Methodology Committee, in Desmedt JE (ed): Progress in Clinical Neurophysiology. Attention, Voluntary Contraction and Event-Related Cerebral Potentials, vol 1. Basel, Karger, 1977, 1–11.

28.

Friedman JM , Riccardi VM : Clinical and epidemiological features, in Friedman JM , Gutmann DH , MacCollin M , Riccardi VM (eds): Neurofibromatosis: Phenotype, Natural History, and Pathogenesis, 3rd ed., Baltimore, Johns Hopkins Press, 1999, 29–86.

29.

DeBella K , Poskitt K , Szudek J , Friedman JM : Use of “unidentified bright objects” on MRI for diagnosis of neurofibromatosis 1 in children. Neurology 2000;54:1646–1651.

30.

Kim G , Mehta M , Kucharzyk W , Blaser S : Spontaneous regression of a tectal mass in neurofibromatosis. AJNR Am J Neuroradiol 1998;19:1137–1139.

31.

Leisti EL , Pytinen J , Poyhonen M : Spontaneous decrease of a pilocytic astrocytoma in neurofibromatosis type 1. AJNR Am J Neuroradiol 1996;17:1691–1694.

32.

Morris PW , Glasier CM , Smirniotopoulos JG , Allison JW : Disappearing enhancing brain lesion in a child with neurofibromatosis type 1. Pediatr Radiol 1997;27:260–261.

33.

Parazzini C , Triulzi F , Bianchini E , et al: Spontaneous involution of optic pathway lesions in neurofibromatosis type 1: Serial contrast MR evaluation. AJNR Am J Neuroradiol 1995;16:1711–1718.

34.

Norfray JF , Darling C , Byrd S , et al: Short TE proton MRS and neurofibromatosis type 1 intracranial lesions. J Comput Assist Tomogr 1999;23:994–1003.

35.

Schmandt SM , Packer RJ , Vezina LG : Spontaneous regression of low-grade astrocytomas in childhood. Pediatr Neurosurg 2000;32:132–136.

36.

North K , Cochineas C , Tang E , Fagan E : Optic gliomas in neurofibromatosis type 1: Role of visual evoked potentials. Pediatr Neurol 1994;10:117–123.

37.

American Academy of Pediatrics Committee on Genetics: Molecular genetic testing in pediatric practice: a subject review. Pediatric 2000;106:1494–1497.